AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?

It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and AstraZeneca's (NASDAQ: AZN) materials are no di https://www.nasdaq.com/articles/astrazeneca-just-joined-the-ai-drug-development-craze-but-is-it-a-buy-in-2024